Erratum to 'Gene therapy for neurodegenerative diseases' [Trends in Molecular Medicine 21 (2015) 504-512] DOI: 10.1016/j.molmed.2015.06.001;Gene therapy for neurodegenerative diseases

Trends in Molecular Medicine

Volumn 21, Issue 8, 2015, Pages 504-512

  O'Connor, Deirdre M ^a   Boulis, Nicholas M ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical trial; Gene therapy; Neurodegenerative disease

Indexed keywords

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; DEGENERATIVE DISEASE; GENE THERAPY; HUMAN; LYSOSOME STORAGE DISEASE; NONHUMAN; OUTCOME ASSESSMENT; PARKINSON DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; SPINAL MUSCULAR ATROPHY; SPINOCEREBELLAR DEGENERATION; TREATMENT RESPONSE; UNIFIED PARKINSON DISEASE RATING SCALE; ADVERSE EFFECTS; ANIMAL; CLINICAL TRIAL (TOPIC); GENETICS; NEURODEGENERATIVE DISEASES; PROCEDURES; TREATMENT OUTCOME;

ANIMALS; CLINICAL TRIALS AS TOPIC; GENETIC THERAPY; HUMANS; NEURODEGENERATIVE DISEASES; TREATMENT OUTCOME;

EID: 84938552922     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2015.12.008     Document Type: Erratum

References (121)

1. Weinberg M.S., et al. Adeno-associated virus (AAV) gene therapy for neurological disease. Neuropharmacology 2013, 69:82-88.
2. Nanou A., Azzouz M. Gene therapy for neurodegenerative diseases based on lentiviral vectors. Prog. Brain Res. 2009, 175:187-200.
3. Duque S., et al. Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol. Ther. 2009, 17:1187-1196.
4. Riley J., et al. Intraspinal stem cell transplantation in amyotrophic lateral sclerosis: a phase I safety trial, technical note, and lumbar safety outcomes. Neurosurgery 2012, 71:405-416.
5. Federici T., et al. Robust spinal motor neuron transduction following intrathecal delivery of AAV9.GFP in pigs. Gene Ther. 2012, 19:852-859.
6. Marks W.J., et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol. 2008, 7:400-408.
7. Rafii M.S., et al. A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease. Alzheimers Dement. 2014, 10:571-581.
8. Leone P., et al. Long-term follow-up after gene therapy for canavan disease. Sci. Transl. Med. 2012, 4:165ra163.
9. Fasano A., et al. Axial disability and deep brain stimulation in patients with Parkinson disease. Nat. Rev. Neurol. 2015, 11:98-110.
10. Bartus R.T., et al. Parkinson's disease gene therapy: success by design meets failure by efficacy. Mol. Ther. 2014, 22:487-497.
11. LeWitt P.A., et al. AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol. 2011, 10:309-319.
12. Marks W.J., et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2010, 9:1164-1172.
13. Bartus R.T., et al. Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease. Neurobiol. Dis. 2011, 44:38-52.
14. Bartus R.T., et al. Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov. Disord. 2011, 26:27-36.
15. Herzog C.D., et al. Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120). Neurobiol. Dis. 2013, 58:38-48.
16. Bartus R.T., et al. Advancing neurotrophic factors as treatments for age-related neurodegenerative diseases: developing and demonstrating 'clinical proof-of-concept' for AAV-neurturin (CERE-120) in Parkinson's disease. Neurobiol. Aging 2013, 34:35-61.
17. Azzouz M., et al. Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic L-amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat model of Parkinson's disease. J. Neurosci. 2002, 22:10302-10312.
18. Palfi S., et al. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. Lancet 2014, 383:1138-1146.
19. Muramatsu S., et al. A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease. Mol. Ther. 2010, 18:1731-1735.
20. Christine C.W., et al. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 2009, 73:1662-1669.
21. Mittermeyer G., et al. Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease. Hum. Gene Ther. 2012, 23:377-381.
22. San Sebastian W., et al. Safety and tolerability of magnetic resonance imaging-guided convection-enhanced delivery of AAV2-hAADC with a novel delivery platform in nonhuman primate striatum. Hum. Gene Ther. 2012, 23:210-217.
23. Cederfjall E., et al. Design of a single AAV vector for coexpression of TH and GCH1 to establish continuous DOPA synthesis in a rat model of Parkinson's disease. Mol. Ther. 2012, 20:1315-1326.
24. Cederfjall E., et al. Continuous DOPA synthesis from a single AAV: dosing and efficacy in models of Parkinson's disease. Sci. Rep. 2013, 3:2157.
25. Ren X., et al. AAV2-mediated striatum delivery of human CDNF prevents the deterioration of midbrain dopamine neurons in a 6-hydroxydopamine induced parkinsonian rat model. Exp. Neurol. 2013, 248:148-156.
26. Back S., et al. Gene therapy with AAV2-CDNF provides functional benefits in a rat model of Parkinson's disease. Brain Behav. 2013, 3:75-88.
27. Georgievska B., et al. Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer. Exp. Neurol. 2002, 177:461-474.
28. Hovland D.N., et al. Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF) in rhesus monkeys. Toxicol. Pathol. 2007, 35:676-692.
29. Manfredsson F.P., et al. Tight long-term dynamic doxycycline responsive nigrostriatal GDNF using a single rAAV vector. Mol. Ther. 2009, 17:1857-1867.
30. Rosenblad C., et al. Long-term striatal overexpression of GDNF selectively downregulates tyrosine hydroxylase in the intact nigrostriatal dopamine system. Eur. J. Neurosci. 2003, 17:260-270.
31. Quintino L., et al. Functional neuroprotection and efficient regulation of GDNF using destabilizing domains in a rodent model of Parkinson's disease. Mol. Ther. 2013, 21:2169-2180.
32. Iwamoto M., et al. A general chemical method to regulate protein stability in the mammalian central nervous system. Chem. Biol. 2010, 17:981-988.
33. Leblond C.S., et al. Dissection of genetic factors associated with amyotrophic lateral sclerosis. Exp. Neurol. 2014, 262:91-101.
34. Miller T.M., et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 2013, 12:435-442.
35. Thomsen G.M., et al. Delayed disease onset and extended survival in the SOD1G93A rat model of amyotrophic lateral sclerosis after suppression of mutant SOD1 in the motor cortex. J. Neurosci. 2014, 34:15587-15600.
36. Foust K.D., et al. Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS. Mol. Ther. 2013, 21:2148-2159.
37. Patel P., et al. Adeno-associated virus-mediated delivery of a recombinant single-chain antibody against misfolded superoxide dismutase for treatment of amyotrophic lateral sclerosis. Mol. Ther. 2014, 22:498-510.
38. Keifer O.P., et al. Gene and protein therapies utilizing VEGF for ALS. Pharmacol. Ther. 2014, 141:261-271.
39. Oosthuyse B., et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat. Genet. 2001, 28:131-138.
40. Dodge J.C., et al. AAV4-mediated expression of IGF-1 and VEGF within cellular components of the ventricular system improves survival outcome in familial ALS mice. Mol. Ther. 2010, 18:2075-2084.
41. Kliem M.A., et al. Intramuscular administration of a VEGF zinc finger transcription factor activator (VEGF-ZFP-TF) improves functional outcomes in SOD1 rats. Amyotroph. Lateral Scler. 2011, 12:331-339.
42. Henriques A., et al. CNS-targeted viral delivery of G-CSF in an animal model for ALS: improved efficacy and preservation of the neuromuscular unit. Mol. Ther. 2011, 19:284-292.
43. Butovsky O., et al. Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. J. Clin. Invest. 2012, 122:3063-3087.
44. Koval E.D., et al. Method for widespread microRNA-155 inhibition prolongs survival in ALS-model mice. Hum. Mol. Genet. 2013, 22:4127-4135.
45. Miller J.N., Pearce D.A. Nonsense-mediated decay in genetic disease: friend or foe? Mutation research. Rev. Mutat. Res. 2014, 762:52-64.
46. Jackson K.L., et al. Preservation of forelimb function by UPF1 gene therapy in a rat model of TDP-43-induced motor paralysis. Gene Ther. 2015, 22:20-28.
47. Grothe M., et al. Atrophy of the cholinergic basal forebrain over the adult age range and in early stages of Alzheimer's disease. Biol. Psychiatry 2012, 71:805-813.
48. Mucke L., Selkoe D.J. Neurotoxicity of amyloid beta-protein: synaptic and network dysfunction. Cold Spring Harb. Perspect. Med. 2012, 2:a006338.
49. Bohm C., et al. Current and future implications of basic and translational research on amyloid-beta peptide production and removal pathways. Mol. Cell. Neurosci. 2015, 66:3-11.
50. Hogan D.B., et al. Long-term efficacy and toxicity of cholinesterase inhibitors in the treatment of Alzheimer disease. Can. J. Psychiatry 2014, 59:618-623.
51. Oddo S., et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003, 39:409-421.
52. Murphy S.R., et al. Acat1 knockdown gene therapy decreases amyloid-beta in a mouse model of Alzheimer's disease. Mol. Ther. 2013, 21:1497-1506.
53. Sud R., et al. Antisense-mediated exon skipping decreases tau protein expression: a potential therapy for tauopathies. Mol. Ther. Nucleic Acids 2014, 3:e180.
54. Iwata N., et al. Metabolism of amyloid-beta peptide and Alzheimer's disease. Pharmacol. Ther. 2005, 108:129-148.
55. Iwata N., et al. Global brain delivery of neprilysin gene by intravascular administration of AAV vector in mice. Sci. Rep. 2013, 3:1472.
56. Carty N., et al. Intracranial injection of AAV expressing NEP but not IDE reduces amyloid pathology in APP+PS1 transgenic mice. PLoS ONE 2013, 8:e59626.
57. Marwarha G., et al. Leptin reduces the accumulation of Abeta and phosphorylated tau induced by 27-hydroxycholesterol in rabbit organotypic slices. J. Alzheimers Dis. 2010, 19:1007-1019.
58. Doherty G.H., et al. Leptin prevents hippocampal synaptic disruption and neuronal cell death induced by amyloid beta. Neurobiol. Aging 2013, 34:226-237.
59. Farr O.M., et al. Leptin and the brain: influences on brain development, cognitive functioning and psychiatric disorders. Metab. Clin. Exp. 2015, 64:114-130.
60. Perez-Gonzalez R., et al. Leptin gene therapy attenuates neuronal damages evoked by amyloid-beta and rescues memory deficits in APP/PS1 mice. Gene Ther. 2014, 21:298-308.
61. Knuesel I., et al. Reelin-mediated signaling in neuropsychiatric and neurodegenerative diseases. Prog. Neurobiol. 2010, 91:257-274.
62. Knuesel I., et al. Age-related accumulation of Reelin in amyloid-like deposits. Neurobiol. Aging 2009, 30:697-716.
63. Kocherhans S., et al. Reduced Reelin expression accelerates amyloid-beta plaque formation and tau pathology in transgenic Alzheimer's disease mice. J. Neurosci. 2010, 30:9228-9240.
64. Herring A., et al. Reelin depletion is an early phenomenon of Alzheimer's pathology. J. Alzheimers Dis. 2012, 30:963-979.
65. Hafez D.M., et al. F-spondin gene transfer improves memory performance and reduces amyloid-beta levels in mice. Neuroscience 2012, 223:465-472.
66. Lustbader J.W., et al. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science 2004, 304:448-452.
67. Zhang Q., et al. Caspase-3 short hairpin RNAs: a potential therapeutic agent in neurodegeneration of aluminum-exposed animal model. Curr. Alzheimer Res. 2014, 11:961-970.
68. Chai X., et al. A viral vector expressing hypoxia-inducible factor 1 alpha inhibits hippocampal neuronal apoptosis. Neural Regen. Res. 2014, 9:1145-1153.
69. Revilla S., et al. Lenti-GDNF gene therapy protects against Alzheimer's disease-like neuropathology in 3×Tg-AD mice and MC65 cells. CNS Neurosci. Therapeutics 2014, 20:961-972.
70. Pascual-Lucas M., et al. Insulin-like growth factor 2 reverses memory and synaptic deficits in APP transgenic mice. EMBO Mol. Med. 2014, 6:1246-1262.
71. Faravelli I., et al. Spinal muscular atrophy - recent therapeutic advances for an old challenge. Nat. Rev. Neurol. 2015, Published online May 19, 2015. 10.1038/nrneurol.2015.77.
72. Donnelly E.M., Boulis N.M. Update on gene and stem cell therapy approaches for spinal muscular atrophy. Expert Opin. Biol. Ther. 2012, 12:1463-1471.
73. Passini M.A., et al. Translational fidelity of intrathecal delivery of self-complementary AAV9-survival motor neuron 1 for spinal muscular atrophy. Hum. Gene Ther. 2014, 25:619-630.
74. Meyer K., et al. Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates. Mol. Ther. 2015, 23:477-487.
75. Foust K.D., et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat. Biotechnol. 2010, 28:271-274.
76. Bevan A.K., et al. Early heart failure in the SMNDelta7 model of spinal muscular atrophy and correction by postnatal scAAV9-SMN delivery. Hum. Mol. Genet. 2010, 19:3895-3905.
77. Duque S.I., et al. A large animal model of spinal muscular atrophy and correction of phenotype. Ann. Neurol. 2015, 77:399-414.
78. Passini M.A., et al. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci. Transl. Med. 2011, 3:72ra18.
79. Staropoli J.F., et al. Rescue of gene-expression changes in an induced mouse model of spinal muscular atrophy by an antisense oligonucleotide that promotes inclusion of SMN2 exon 7. Genomics 2015, 105:220-228.
80. Shakkottai V.G., Fogel B.L. Clinical neurogenetics: autosomal dominant spinocerebellar ataxia. Neurol. Clin. 2013, 31:987-1007.
81. Nobrega C., et al. Silencing mutant ataxin-3 rescues motor deficits and neuropathology in Machado-Joseph disease transgenic mice. PLoS ONE 2013, 8:e52396.
82. Rodriguez-Lebron E., et al. Silencing mutant ATXN3 expression resolves molecular phenotypes in SCA3 transgenic mice. Mol. Ther. 2013, 21:1909-1918.
83. Alves S., et al. Silencing ataxin-3 mitigates degeneration in a rat model of Machado-Joseph disease: no role for wild-type ataxin-3?. Hum. Mol. Genet. 2010, 19:2380-2394.
84. Keiser M.S., et al. Broad therapeutic benefit after RNAi expression vector delivery to deep cerebellar nuclei: implications for spinocerebellar ataxia type 1 therapy. Mol. Ther. 2014, 22:588-595.
85. Ramachandran P.S., et al. RNA interference-based therapy for spinocerebellar ataxia type 7 retinal degeneration. PLoS ONE 2014, 9:e95362.
86. Bradbury A.M., et al. A review of gene therapy in canine and feline models of lysosomal storage disorders. Hum. Gene Ther. Clin. Dev. 2015, 26:27-37.
87. Pastores G.M., Hughes D.A. Non-neuronopathic lysosomal storage disorders: disease spectrum and treatments. Best Pract. Res. Clin. Endocrinol. Metab. 2015, 29:173-182.
88. Kishnani P.S., et al. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol. Genet. Metab. 2010, 99:26-33.
89. Mah C., et al. Physiological correction of Pompe disease by systemic delivery of adeno-associated virus serotype 1 vectors. Mol. Ther. 2007, 15:501-507.
90. Mah C.S., et al. Gel-mediated delivery of AAV1 vectors corrects ventilatory function in Pompe mice with established disease. Mol. Ther. 2010, 18:502-510.
91. Smith B.K., et al. Phase I/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes. Hum. Gene Ther. 2013, 24:630-640.
92. Elmallah M.K., et al. Sustained correction of motoneuron histopathology following intramuscular delivery of AAV in pompe mice. Mol. Ther. 2014, 22:702-712.
93. Falk D.J., et al. Intrapleural administration of AAV9 improves neural and cardiorespiratory function in Pompe disease. Mol. Ther. 2013, 21:1661-1667.
94. Qiu K., et al. Spinal delivery of AAV vector restores enzyme activity and increases ventilation in Pompe mice. Mol. Ther. 2012, 20:21-27.
95. Han S.O., et al. Enhanced efficacy from gene therapy in Pompe disease using coreceptor blockade. Hum. Gene Ther. 2015, 26:26-35.
96. van Rappard D.F., et al. Metachromatic leukodystrophy: disease spectrum and approaches for treatment. Best Pract. Res. Clin. Endocrinol. Metab. 2015, 29:261-273.
97. Piguet F., et al. Correction of brain oligodendrocytes by AAVrh.10 intracerebral gene therapy in metachromatic leukodystrophy mice. Hum. Gene Ther. 2012, 23:903-914.
98. Miyake N., et al. Long-term correction of biochemical and neurological abnormalities in MLD mice model by neonatal systemic injection of an AAV serotype 9 vector. Gene Ther. 2014, 21:427-433.
99. Valstar M.J., et al. Mucopolysaccharidosis type IIIA: clinical spectrum and genotype-phenotype correlations. Ann. Neurol. 2010, 68:876-887.
100. Tardieu M., et al. Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I/II trial. Hum. Gene Ther. 2014, 25:506-516.
101. Duncan F.J., et al. Broad functional correction of molecular impairments by systemic delivery of scAAVrh74-hSGSH gene delivery in MPS IIIA mice. Mol. Ther. 2015, 23:638-647.
102. Haurigot V., et al. Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy. J. Clin. Invest. 2013, 123:3254-3271.
103. Ruzo A., et al. Correction of pathological accumulation of glycosaminoglycans in central nervous system and peripheral tissues of MPSIIIA mice through systemic AAV9 gene transfer. Hum. Gene Ther. 2012, 23:1237-1246.
104. Champion K.J., et al. Identification and characterization of a novel homozygous deletion in the alpha-N-acetylglucosaminidase gene in a patient with Sanfilippo type B syndrome (mucopolysaccharidosis IIIB). Mol. Genet. Metab. 2010, 100:51-56.
105. Fu H., et al. Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery. Mol. Ther. 2011, 19:1025-1033.
106. Ribera A., et al. Biochemical, histological and functional correction of mucopolysaccharidosis type IIIB by intra-cerebrospinal fluid gene therapy. Hum. Mol. Genet. 2015, 24:2078-2095.
107. Murrey D.A., et al. Feasibility and safety of systemic rAAV9-hNAGLU delivery for treating mucopolysaccharidosis IIIB: toxicology, biodistribution, and immunological assessments in primates. Hum. Gene Ther. Clin. Dev. 2014, 25:72-84.
108. Kakkis E.D., et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N. Engl. J. Med. 2001, 344:182-188.
109. Wolf D.A., et al. Increased longevity and metabolic correction following syngeneic BMT in a murine model of mucopolysaccharidosis type I. Bone Marrow Transplant. 2012, 47:1235-1240.
110. Janson C.G., et al. Comparison of endovascular and intraventricular gene therapy with adeno-associated virus-alpha-l-iduronidase for Hurler disease. Neurosurgery 2014, 74:99-111.
111. Hinderer C., et al. Intrathecal gene therapy corrects CNS pathology in a feline model of mucopolysaccharidosis I. Mol. Ther. 2014, 22:2018-2027.
112. Denny C.A., et al. Influence of caloric restriction on motor behavior, longevity, and brain lipid composition in Sandhoff disease mice. J. Neurosci. Res. 2006, 83:1028-1038.
113. Sargeant T.J., et al. Adeno-associated virus-mediated expression of beta-hexosaminidase prevents neuronal loss in the Sandhoff mouse brain. Hum. Mol. Genet. 2011, 20:4371-4380.
114. Rockwell H.E., et al. AAV-mediated gene delivery in a feline model of Sandhoff disease corrects lysosomal storage in the central nervous system. ASN Neuro. 2015, 7. Published online April 13, 2015. 10.1177/1759091415569908.
115. McCurdy V.J., et al. Widespread correction of central nervous system disease after intracranial gene therapy in a feline model of Sandhoff disease. Gene Ther. 2015, 22:181-189.
116. Bartus R.T., et al. Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. Neurology 2013, 80:1698-1701.
117. Foust K.D., et al. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat. Biotechnol. 2009, 27:59-65.
118. Wurtman R. Biomarkers in the diagnosis and management of Alzheimer's disease. Metab. Clin. Exp. 2015, 64(Suppl. 1):S47-S50.
119. Bakkar N., et al. Use of biomarkers in ALS drug development and clinical trials. Brain Res. 2015, 1607:94-107.
120. Blennow K., et al. Amyloid biomarkers in Alzheimer's disease. Trends Pharmacol. Sci. 2015, 36:297-309.
121. Magdalinou N., et al. Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions. J. Neurol. Neurosurg. Psychiatry 2014, 85:1065-1075.